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SPINK9: A Selective, Skin-Specific Kazal-Type Serine
Protease Inhibitor
Maria Brattsand1, Kristina Stefansson1, Thomas Hubiche1, Stefan K. Nilsson1 and Torbjo¨rn Egelrud1
A previously unreported Kazal-type serine protease inhibitor, serine protease inhibitor Kazal type 9 (SPINK9),
was identified in human skin. SPINK9 expression was strong in palmar epidermis, but not detectable or very low
in non palmoplantar skin. Analysis of a human cDNA panel showed intermediate expression in thymus,
pancreas, liver, and brain, and low or undetectable expression in other tissues. Using kallikrein-related
peptidases (KLKs) 5, 7, 8, and 14, thrombin, trypsin, and chymotrypsin, inhibition with recombinant SPINK9 was
seen only for KLK5 using low molecular weight substrates, with an apparent Ki of 65 nM. Also KLK5 degradation
of fibrinogen was totally inhibited by SPINK9. Slight inhibition of KLK8 using fibrinogen substrate could be
observed using high concentrations of SPINK9. Analyses by surface plasmon resonance showed heterogeneous
binding to SPINK9 of KLK5 and KLK8, but no binding of KLK7 or KLK14. KLK5 has been suggested to play a central
role in skin desquamation as an initiating activating enzyme in proteolytic cascades formed by KLKs. An
apparently KLK5-specific inhibitor, such as SPINK9, may play a significant regulatory role in such cascades. We
suggest a possible role for SPINK9 in the site-specific epidermal differentiation of palms and soles.
Journal of Investigative Dermatology (2009) 129, 1656–1665; doi:10.1038/jid.2008.448; published online 5 February 2009
INTRODUCTION
The importance of serine protease inhibitors and, deduc-
tively, of a well-regulated activity of serine proteases in skin
homeostasis was shown when the genetic background of the
Comel–Netherton syndrome (OMIM 256500) was unraveled.
A defective skin barrier is a major feature of this severe
disease, leading to excessive loss of water and electrolytes in
the newborn, and a scaly, inflamed, itchy skin, highly prone
to infections. The disease is caused by loss-of-function
mutations in the serine protease inhibitor Kazal type 5
(SPINK5) gene, encoding the multidomain serine protease
inhibitor LEKTI (lymphoepithelial Kazal-type related inhibi-
tor). The skin barrier deficiency is believed to be the result of
the ensuing elevated activity of serine proteases in the
epidermis, leading to an increased rate of degradation of
intercellular cohesive structures in the superficial cornified
layer, the stratum corneum (Ma¨gert et al., 1999; Chavanas
et al., 2000; Sprecher et al., 2001; Walley et al., 2001;
Komatsu et al., 2002; Hachem et al., 2006). Supporting
evidence has been obtained in animal studies, including
generation of SPINK5/ mice (that mimic the Netherton
phenotype) and transgenic mice overexpressing epidermal
serine proteases (Ny and Egelrud, 2004; Yang et al., 2004;
Descargues et al., 2005).
Epidermal serine proteases suggested to be responsible for
the phenotypic skin changes seen in Comel–Netherton
syndrome belong to the tissue kallikreins, also named
kallikrein-related peptidases (KLKs) (Lundwall et al., 2006).
Human KLKs is a group consisting of 15 related members
with genes located on a 450 kb segment on the short arm of
chromosome 19 (Yousef et al., 1999; Harvey et al., 2000).
KLKs are expressed by a wide variety of tissues. During the
past decade, there has been a lot of focus on potential roles
of KLKs as tumor markers, in tumor progression, activation
of protease-activated receptors, and activation/inactivation of
biologically active peptides (Borgon˜o et al., 2004; Clements
et al., 2004; Oikonomopoulou et al., 2006; Yamasaki et al.,
2006; Stefansson et al., 2008). In the skin, two proteases
eventually identified as KLK5 (previously stratum corneum
tryptic enzyme) and KLK7 (previously stratum corneum
chymotryptic enzyme) have been suggested to be involved
in skin homeostasis and desquamation (Hansson et al., 1994;
Brattsand and Egelrud, 1999). Also several other KLKs, among
them KLKs 6, 8, 9, 11, 13, and 14, are expressed by the
epidermis (Komatsu et al., 2003). As KLKs are produced as
catalytically inactive zymogen precursors, which can be
activated by proteolytic removal of their respective propep-
tide, it has been proposed that they may function as parts of
proteolytic cascades, analogous to, for example, enzymes
involved in blood coagulation or complement activation. In
this respect, KLK5 has received special attention, as among
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the KLKs it appears to be the most multipotent activator of
KLK precursors, including its own precursor by auto
activation (Brattsand et al., 2005; Yoon et al., 2007).
The presence of a set of proteases with different catalytic
properties and substrate specificities in a tissue such as the
stratum corneum suggests the presence in the tissue also of
intricate regulatory mechanisms. These mechanisms may
include zymogen activation, inactivation by degradation, and
regulation by physical–chemical parameters, such as pH,
water content, and ionic composition (Egelrud, 1993;
Watkinson et al., 2001; Caubet et al., 2004; Brattsand
et al., 2005; Deraison et al., 2007). The presence of specific
inhibitors may, as illustrated above, play a crucial role. In our
efforts to understand the interplay between serine proteases
and various inhibitors of these enzymes present in human
stratum corneum, we identified a hitherto not described
Kazal-type serine protease inhibitor. Here, we report on
purification, recombinant production, and tissue expression
of this new inhibitor, tentatively named ‘‘SPINK9,’’ encoded
by the human gene SPINK9. We also studied its interactions
and inhibitory properties with a set of proteases. Our results
suggest a high degree of specificity of SPINK9 as regard its
inhibitory profile as well as its tissue expression pattern.
RESULTS
By means of reversed-phase chromatography, fractions with
inhibitory activity toward several serine proteases could be
separated from fractions containing protease activity, as
shown for KLK5 in Figure 1a. Results from analyses of
inhibitory activity of each fraction toward individual
enzymes, and from immunoblot analyses with antibodies to
known inhibitors expected to be present in extracts of stratum
corneum (results not shown), implied that the fractions
contained an unidentified inhibitor. After further purification
(see Materials and Methods), three bands could be visualized
after separation on SDS-PAGE (see Figure 1b). Using mass
spectrometry, band no. I could be identified as being derived
from keratin. Band II could not be identified, whereas band III
was identified (expectation value e12.51, 6 out of 24 masses
were matched and a sequence coverage of 50.6%) as the
putative SPINK9 (alias LEKTI2, accession no. AY396740;
NP_001035523; gene SPINK9, GeneID: 643394; chromo-
some 5q33.1). The identity could be further verified by
conventional N-terminal amino-acid sequence analysis
(Figure 2b). There was a K/Q mismatch between purified
and deduced protein; this was not further studied.
Recombinant SPINK9
Computer analysis of the amino-acid sequence deduced from
cDNA (SignalP; www.expasy.org/tools/) predicted signal
cleavage between amino acids 19 and 20 (FS-IE). Primer
pairs were designed from the published cDNA sequence.
PCR amplification of cDNA from HaCaT cells using the
primer pair SPINK9F1–SPINK9R1 (see Figure 2c), designed to
yield a product encoding the entire protein, including the
signal peptide, resulted in a fragment containing, in addition
to open reading frames encoding the entire protein, the first
intron downstream the open reading frame of the postulated
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Figure 1. Characterization of proteins with KLK5-inhibiting activity in
plantar stratum corneum and recombinant SPINK9. (a) An acetic acid extract
of plantar stratum corneum was subjected to reversed-phase chromatography.
Recombinant KLK5 was added to samples of each fraction, which were then
analyzed for activity toward the substrate S-2288. Hundred percent activity
corresponds to activity when fraction samples were substituted with 0.1%
trifluoroacetic acid. The high activity seen in fraction nos. 17–23 is due to the
activity of proteolytic enzymes present in the extract. KLK5-inhibiting activity
was found in fraction nos. 9–15. For further details, see Supplementary
Materials & Methods. (b) Proteins purified from plantar stratum corneum;
Coomassie blue staining. Bands labeled I–III were excised from the gel and
subjected to matrix-associated laser desorption ionization-time of flight
analysis (see text for details). (c) Comparison of SPINK9 in plantar stratum
corneum and recombinant SPINK9; Coomassie blue staining and (d)
immunoblot with SPINK9 specific antibodies. Lane 1: recombinant SPINK9;
lane 2: sample from fraction corresponding to no. 13 in (a). Reduced samples,
polyacrylamide 10–20% gradient in (b), 15% in (c, d). In (c), 2 mg recombinant
SPINK9 and 18 mg protein from fraction no. 13 were loaded onto the gel. In
(d), one-tenth of the amounts in (c) were loaded. The difference in size
between native and recombinant SPINK9 is explained by additional
N-terminal amino acids in the recombinant protein (see text and Figure 2). (e)
Mass spectrometry spectrum showing the purity of the recombinant protein.
The peak at mass-to-charge ratio (m/z) 7726.458 corresponds to monomeric
SPINK9, whereas a mass-to-charge ratio of 15458.161 corresponds to SPINK9
in dimeric form.
www.jidonline.org 1657
M Brattsand et al.
SPINK9
signal peptide. This fragment could be used as template to
amplify a cDNA encoding the postulated secreted protein,
that is, the whole protein excluding the signal peptide, six
amino-acid residues longer at the N-terminal end than the
purified native protein (Figure 2a–c).
Analysis by mass spectrometry of recombinant SPINK9
after enterokinase cleavage and subsequent purification
showed a pure protein with the correct N terminus and a
calculated molecular mass of 7731 Da (theoretical value
7726). A dimer form of the protein was also observed
(see Figure 1e). A comparison of recombinant SPINK9 with
the corresponding native protein by SDS-PAGE and immuno-
blotting is shown in Figure 1c and d. As expected from
amino-acid sequence analyses, the native protein, having six
fewer N-terminal amino-acid residues, had a slightly smaller
apparent molecular mass (Figures 1c, d and 2b).
Figure 2. Human Kazal inhibitor sequences. (a) The SPINK9 cDNA sequence (accession no AY396740) with the postulated amino-acid sequence shown below in
one code letter. Italics denote postulated signal sequence; asterisk denotes N-terminal residue in SPINK9 purified from plantar stratum corneum. (b) Comparison of N-
terminal amino-acid sequences for SPINK9 purified from plantar stratum corneum (sc), recombinant SPINK9 corresponding to sc variant but based on cDNA sequence
(epSPINK9) and recombinant full-length SPINK9 postulated from cDNA sequence (SPINK9). (c) A schematic picture of the SPINK9 gene, where exons are symbolized
by unbroken lines and the introns by dotted triangles. The sizes of exons and introns are indicated in the figure. The two putative start methionines are indicated as M,
and the postulated first amino acids (IEC) after the predicted signal cleavage site are visualized. The arrows above the cDNA line symbolize the primer pairs used in
different PCR experiments. (d) Comparison of amino-acid sequences of known human Kazal-type or Kazal-like serine protease inhibitors. The Kazal consensus
sequence (http://expasy.org/tools/scanprosite/) is shown on the first line. d1-d15 depicts Kazal or Kazal-like LEKTI domains of SPINK5. Bold letters show consensus
residues. Bold letters in italics show P1–P10 of postulated active sites. Suggested S–S bonds are indicated by dashes (Ma¨gert et al., 1999).
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Protein–protein interaction studies
To investigate possible interactions between SPINK9 and
KLK5, KLK7, KLK8, and KLK14, surface plasmon resonance
technology was used. KLK7 and KLK14 were found not to
interact with SPINK9. In accordance with inhibition experi-
ments (see below), KLK5 showed high affinity for SPINK9.
KLK8 also showed affinity for SPINK9; however, this
interaction was markedly weaker. When evaluating KLK5
and KLK8 interactions with SPINK9, a simple Langmuir 1:1
model was insufficient to describe the binding. Both
interactions were characterized by heterogeneity, that is,
two parallel binding reactions. KLK5 showed kinetic
parameters, indicating one rapid and one slower association rate
constant; Ka1¼1.2 106 M1 s1 and Ka2¼6.6 104 M1 s1.
Corresponding dissociation rate constants were
Kd1¼ 0.0059 s1 and Kd2¼ 0.042 s1 (Figure 3a). From these
values, two dissociation constants were calculated,
KD1¼5.1 109 M and KD2¼6.3107 M. Corresponding
kinetic parameters for KLK8 were Ka1¼4.6 104 M1 s1,
Ka2¼8.0103 M1 s1, Kd1¼0.0022s1, and Kd2¼ 0.017s1.
Dissociation constants for KLK8 were KD1¼ 4.8108 M and
KD2¼2.2 106 M (Figure 3b).
Figure 3c shows plotted steady-state values of binding
of KLK5 and KLK8 to SPINK9. A double rectangular
four parameter regression model was used to calculate
dissociation constants [Y¼ ax/(bþ x)þ cx/(dþ x)], yielding
KD1¼1.1 108 M and 2.5 107 M, and KD2¼1.0 106 M
and 5.2106 M for KLK5 and KLK8, respectively, confirm-
ing the difference in affinity for SPINK9 between the two
enzymes, as well as the heterogeneity of the binding
reactions.
Inhibition of serine proteases by SPINK9
Among the enzymes tested (bovine trypsin, bovine chymo-
trypsin, human thrombin, human KLK5, KLK7, KLK8, and
KLK14), significant inhibition by recombinant SPINK9 could
be shown only for KLK5. By determining EC50 at different
enzyme concentrations, an apparent Ki of around 65 nM at pH
8 could be estimated. Lowering the pH to 5.5 gave
comparable results for Ki and had no effect on specificity
(data not shown). Control experiments performed with a
recombinant protein corresponding to the native SPINK9
purified from epidermis (denoted as epSPINK9), that is, six
amino acids shorter, showed similar results. Figure 4a and b
shows results for the four KLKs with chromogenic peptide
substrates, and Figure 4c shows results for the four KLKs with
a casein substrate. The activity of KLK8 toward casein was too
low to allow for testing of inhibitor activity.
As KLK8 showed essentially undetectable activity toward
the casein substrate, a fibrinogen assay was used to further
analyze the inhibitory activity of SPINK9. As can be seen in
Figure 4d, KLK8 could degrade fibrinogen, but only at a very
low rate as compared with KLK5. Also the degradation
pattern differed. Whereas KLK5 preferentially degraded the a-
chain, KLK8 appeared to be most efficient toward the b-
chain. Figure 4e shows that high concentrations of SPINK9
(7.5 mM) result in a slight reduction of the KLK8 degradation of
fibrinogen, whereas at these inhibitor concentrations, fibrino-
gen degradation by KLK5 was completely abolished. Already
at 55 nM SPINK9, significant inhibition of KLK5 could be
observed (data not shown). No inhibition could be detected
with KLK7 or KLK14 in this assay (data not shown).
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Figure 3. Surface plasmon resonance analyses of binding of KLK5 and KLK8
to SPINK9. SPINK9 was immobilized on CM5 sensor chips. For baseline
subtraction and reference, an empty flow cell was used. Binding studies were
performed at 25 1C in HBS-EP buffer, pH 7.4. Dissociation constants and
kinetic parameters are presented in the related panel. The arrows in (a and b)
indicate the end of the sample injections when the flow was changed to buffer
only. Calculated parameters (see text for details) to the right. Binding of (a)
KLK5 and (b) KLK8 to immobilized SPINK9, KLK5 (2.0 nM–9.4mM), and KLK8
(19 nM–4.8 mM) at 11 different concentrations each were injected. The figures
show selected concentrations of injected enzymes. A total of 1,000 resonance
units correspond to approximately 1 ng protein per mm2. (c) Steady-state
binding of KLK5 (filled circles) and KLK8 (open circles) to SPINK9.
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Expression studies
In contrast to extracts of palmoplantar stratum corneum, in
which SPINK9 could be easily detected, it was not possible to
show the presence of SPINK9 in extracts of nonpalmoplantar
stratum corneum by immunoblotting (results not shown).
This apparent selective expression of SPINK9 in palms and
soles was supported by immunohistochemical analyses.
Whereas LEKTI and KLK5 showed the expected labeling
pattern, that is, of the stratum granulosum and stratum
corneum in palmar as well as in gluteal skin, specific labeling
with antibodies specific for SPINK9 was seen only in the
upper layers of palmar skin (Figure 5).
Highly selective expression of SPINK9 by human tissues
could be shown also at the mRNA level. Figure 6 shows
results from reverse transcriptase PCR with a primer pair
designed to allow amplification of cDNA from the last two
exons. In Figure 6a, RNA from palmar and gluteal skin from
three individuals was analyzed. Figure 6b shows results for
palmar skin and a commercial cDNA panel. At low number
(25) of PCR cycles, an expected amplification product
(248 bp) was obtained only from palmar RNA. After 30
cycles this product could be detected also in thymus,
pancreas, liver, and brain, and after 35 cycles in all tissues
except leukocytes and one out of three samples of gluteal
skin.
In addition to the expected 248 bp product, a larger
product was seen at higher numbers of PCR cycles in the
cDNA panel. Nucleotide sequencing revealed that it con-
tained the last intron, in addition to exon derived sequences
(expected 1,310 bp). The intron sequence contains several
stop codons, so no obvious open reading frame that could
lead to a functional protein could be detected when
translating the sequence. As control experiments (DNase
treatment of RNA prior to cDNA synthesis and exclusion of
the RT step) cannot be performed on the MTC panel, it cannot
be excluded that the larger products seen in Figure 6b is due
to trace amounts of genomic DNA in the samples, although
this has never been observed with any other transcripts
amplified from the same template (Brattsand and Egelrud,
1999). For HaCaT cells (see above) there was evidence of true
intron retention (Galante et al., 2004). Amplification from
other templates, like lymphomas and ovarian cancer tumors,
have in some cases given rise to the same 1,310 bp product.
In those cases, control experiments could exclude genomic
contamination (data not shown). It is well known that RNA
splicing can differ in various organs and may be an important
regulatory factor (Hughes, 2006). The presence in the palmar
skin of full-length, fully spliced mRNA could be confirmed
with reverse transcriptase PCR using the primer pairs
SPINK9F1–SPINK9as1 and subsequent nucleotide sequencing
(results not shown). All analyzed clones (n¼5 from different
sources) confirmed the nucleotide sequence that had been
deposited in the database.
DISCUSSION
We isolated from human plantar stratum corneum a hitherto
not described Kazal-type serine protease inhibitor. By
database searches, this inhibitor could be identified as
SPINK9. The sequence of the corresponding mRNA, prepared
from the skin, had been deposited in 2003 by Wu, Bartels,
and Schroeder (http://www.ncbi.nlm.nih.gov/entrez/viewer.
fcgi?val=AY396740.1), who suggested the tentative
name ‘‘lymphoepithelial Kazal-type-related inhibitor 2;
LEKTI2.’’ Searches for amino-acid sequence similarities
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Figure 4. Inhibitory profile of SPINK9 with different substrates. (a and b) Fractional activity (FA) toward chromogenic substrates (0.5 Km for each enzyme)
after incubation with inhibitors at concentrations depicted. Open circles¼KLK5; upward triangles¼KLK7; downward triangles¼KLK8; diamonds¼KLK14.
(c) FA with fluorescent casein substrate. Symbols as in (a). See text and Supplementary Materials and Methods for details. (d and e) Activity and inhibition by
SPINK9 of KLK5 and KLK8 with fibrinogen as substrate. Proteins were separated on 12% SDS-PAGE and stained overnight using PageBlue (Fermentas,
Lithuania). For further details, see Supplementary Materials and Methods. The a, b, and g chains of fibrinogen are indicated on each side of the figures. In (d),
KLK5 and KLK8 were incubated with fibrinogen for different periods of time as indicated in the figure. In (e), the enzymes were incubated in the presence of
different concentrations of SPINK9 (in mM) as shown in the figure. Incubations were performed for 45 minutes (KLK5) or 22.5 hours (KLK8).
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(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) identified three
highly homologous proteins; in Pan troglodytes (97%
identity, 98% positives), Macaca mulatta (89% identity, 96
% positives), and in Equus caballus (69% identity, 79%
positives).
Known human Kazal-type serine protease inhibitors are
listed in Table 1. The corresponding amino-acid sequences
with the reactive cleavage sites in bold italics (Laskowski and
Kato, 1980) are shown in Figure 2d. The cleavage site and
nearby residues of SPINK9 (P2P20 ¼HHMY) appear to be
unique for SPINK9. Among 471 entries in the Laskowski
database of Kazal inhibitors (http://www.chem.purdue.edu/
LASKOWSKI), there are 0, 2, 2, and 169 reports of H, H, M,
and Y in positions P2, P1, P10, and P20, respectively.
Palmar skin
Gluteal skin
SPINK9 KLK5LEKTI
Figure 5. Immunohistochemical localization of LEKTI, SPINK9, and KLK5 in human skin. Representative immunostaining of normal palmar skin (upper row)
and gluteal skin (lower row). Bar¼200 mm (upper row) or 100mm (lower row).
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Figure 6. mRNA expression of SPINK9 in human tissues. (a) Reverse transcriptase PCR analyses of gluteal (N) or palmar (P) skin from three individuals using
SPINK9 cDNA-specific primer pairs. Keratin 14 was used as a control for amount of epidermal mRNA. (b) Comparison of SPINK9 expression in palmar
epidermis (Ep palm) with 16 other human tissues (MTC panel I and II from Clontech). The amplified cDNA and the number of PCR cycles are specified to the
right. G3PDH is used as a standard for the amount of template present.
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Comparable results were obtained using the PROSITE tool
(http://expasy.org/tools/scanprosite/).
The uncommon amino-acid sequence of the reactive site
of SPINK9 may be reflected in the seemingly high selectivity
as regards enzymes toward which the inhibitor is active. Of
the seven enzymes we tested, among which four were KLKs
present in skin, only KLK5 was significantly inhibited by
SPINK9. It is tempting to speculate that this apparent
specificity for KLK5 may have physiological relevance. KLKs
are produced as inactive precursors that are converted to
active enzymes by proteolytic modifications. They are
believed to interact in proteolytic cascades in which certain
KLKs serve as activators of others. In this respect, KLK5 has
autocatalytic activity, and is the most omnipotent among the
KLKs as regards ability to activate precursors of other KLKs.
KLK5 is the only enzyme known so far that can activate KLK7,
a protease responsible for a major part of the total proteolytic
activity in the stratum corneum (Brattsand et al., 2005; Yoon
et al., 2007). KLK5 may thus play a key role as an initiating
enzyme in KLK cascades, with special demands on regulation
of its activity giving rise to the evolution of specific inhibitors,
such as SPINK9.
Serine protease inhibitor Kazal type 9 appears to have high
specificity with regard to also tissue expression. We found
high expression only in epidermis from palms and soles. By
immunohistochemistry, western blot (data not shown), as
well as reverse transcriptase PCR, a marked difference in
SPINK9 expression between the skin from palms and soles
and the skin from other parts of the body was seen. These
differences may reflect structural and functional differences
between the two types of skin. Palmoplantar stratum
corneum has a high resistance to mechanical trauma,
reflected by a different pattern of corneodesmosomal
degradation as compared with stratum corneum at other
body sites. Studies on desmosomal proteins and desmosome
frequency have shown that, with the exception of regions of
interdigitation between corneocyte edges, desmosomes dis-
appear in the lower stratum corneum of nonpalmoplantar
epidermis, whereas they persist all the way up to the
desquamating corneocytes in palmoplantar epidermis
(Skerrow et al., 1989; Serre et al., 1991). As desmosomes
are responsible for the mechanical integrity of the stratum
corneum, and desmosomal proteins are suggested substrates
of KLKs in this tissue, and as KLK5 may be a key enzyme in
the activation of other KLKs, it is possible that the expression
of SPINK9 may be part of the epidermal differentiation
program specific for palmoplantar skin. As revealed by PCR,
the second highest expression of SPINK9, next to palmar skin,
was seen in the thymus and pancreas. These findings imply a
role for SPINK9 in immunology and may, in spite of very low
expression seen in other epithelial organs, give a rational for
the proposed name ‘‘LEKTI2.’’
As far as we know, there are no monogenetic skin d
iseases preferentially affecting palms and soles for which the
disease-causing mutations have been localized to the same
chromosomal region as SPINK9 (chromosome 5q33.1). In
spite of this, a role of SPINK9 in skin pathophysiology cannot
be excluded. In this respect, diseases such as dyshidrotic
eczema and pustulosis palmoplantaris may be interesting
candidates for further studies. Interestingly, patients suffering
from Netherton syndrome often show no symptoms in their
palms and soles, suggesting the possibility that perhaps
partially redundant SPINK9 in palmoplantar skin may
‘‘rescue’’ SPINK5 mutations in this disease (Smith et al.,
1995).
Surface plasmon resonance (SPR) analyses showed sig-
nificant binding of KLK8 to SPINK9, although with lower
affinity than for KLK5. Using low molecular weight substrates,
we could not show inhibition by SPINK9 of KLK8, not even at
high concentrations of the inhibitor. Using the high mole-
cular weight substrate fibrinogen, we could show a slight
inhibition by SPINK9 using high, probably nonphysiological
concentrations of the inhibitor (Figure 4d). Even at the high
concentrations used, not all KLK8 fibrinogen degradation
activity could be inhibited. This is compatible with a model,
where SPINK9 binds to a site different from the catalytic site
of KLK8 and sterically inhibits interactions with large
substrates but not with low molecular weight substrates.
Table 1. Summary of the different SPINK genes and their products
Gene name Accession no Protein name Linked diseases References
SPINK1,31 NP_003113 Pancreatic trypsin inhibitor (PSTI) Pancreatitis (Chen et al., 2000; Witt et al., 2000)
SPINK2 NP_066937 Acrosin-trypsin inhibitor (HUSI-II) Infertility (Rockett et al., 2004)
SPINK4 NP_055286 Serine peptidase inhibitor, Kazal-type 4, PEC-60 Unknown
SPINK5 NP_006837 Lymphoepithelial Kazal-type 5 inhibitor (LEKTI) Netherton syndrome (Chavanas et al., 2000)
SPINK6 NP_995313 Serine protease inhibitor, Kazal-type 6 Unknown
SPINK7 NP_115955 Esophagus cancer-related gene-2 Esophagus cancer (Yue et al., 2004; Kaifi et al., 2007)
SPINK8 NP_001073994 Serine peptidase inhibitor, Kazal-type 8 Unknown
SPINK9 NP_001035523 Serine peptidase inhibitor, Kazal-type 9,
Lymphoepithelial Kazal-type-related inhibitor 2 (LEKTI2)2
Unknown
1SPINK1 and SPINK3 are identical.
2Name suggested by Wu Z., Bartels J. and Schroeder J.M., direct database submission of cDNA sequence.
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The fact that SPINK9 was an efficient inhibitor of KLK5 with
low molecular as well as high molecular weight substrates
suggests that SPINK9 is indeed interacting with KLK5 at or
very close to the active site of the enzyme.
The SPR results showed heterogeneity in binding of
SPINK9 to KLK5 and KLK8. For both enzymes, a best fit of
observed data was obtained assuming two separate binding
reactions. This suggests other types of interactions than what
would be expected according to the proposed standard
mechanism of interaction between Kazal-type inhibitors and
serine proteases (Laskowski and Kato, 1980). Hypothetically,
KLK5—for which catalytic activity could be effectively
inhibited by SPINK9—has one high affinity binding site for
SPINK9 according to the standard mechanism, and one
binding site with lower affinity. Correspondingly, KLK8 may
bind SPINK9 at sites not involved in catalysis, as discussed
above. An alternative explanation is that our preparation of
recombinant SPINK9 is heterogeneous. As we produced
recombinant SPINK9 in bacteria, we cannot rule out
misfolding of part of the preparation used in the experiments.
As inhibitor concentrations were calculated from protein
concentration in our kinetic analyses, we may have
underestimated the inhibitory efficiency of SPINK9 toward
KLK5.
Although the observed Ki for inhibition by SPINK9 of KLK5
may be low enough to be physiologically relevant, it is high
as compared with corresponding values for the most efficient
LEKTI peptides (Schechter et al., 2005; Deraison et al., 2007).
As we did not investigate the effect of SPINK9 on all serine
proteases known to be produced by the epidermis, we cannot
exclude that other proteases are ‘‘the true targets’’ for this
inhibitor. It is also possible that SPINK9 has other physiolo-
gical functions, as it was recently reported that SPINK9 has
antimicrobial activity (Wu et al., 2008). Novel protease
targets as well as physiological functions of SPINK9 in skin
and other tissues will be the scope of further studies.
MATERIALS AND METHODS
Recombinant enzymes
Recombinant KLK5 was produced as a fusion protein, with the
propeptide of KLK7 mutated with an enterokinase site in the end,
fused with the catalytically active part of KLK5. For further details, see
Supplementary Materials and Methods. Production of recombinant
KLK7, KLK8, and KLK14 has been described elsewhere (Brattsand
et al., 2005; Stefansson et al., 2006, 2008). Trypsin was purchased
from Boehringer Mannheim (Mannheim, Germany). Active site
titration of proteases was carried out as described (Brattsand et al.,
2005).
Protein purification and characterization
Proteins were extracted from dry plantar stratum corneum (Egelrud,
1993) in acetic acid as described (Stefansson et al., 2006) and
subjected to reversed-phase chromatography (RPC) (Brattsand and
Egelrud, 1999). Fractions were screened for inhibitory activity
toward KLK5 as described below and in the legend to Figure 1
(Brattsand et al., 2005). Fractions showing inhibitory activity (nos.
9–15, see Figure 1a) from four different preparations were pooled
and subjected to a second run of RPC. The fraction showing highest
inhibitory activity against KLK5 was concentrated, further fractio-
nated by gel exclusion chromatography (Stefansson et al., 2006), and
submitted to a third run of RPC. For identification of purified proteins
by mass spectrometry, samples of inhibitor-containing fractions from
the final RPC were evaporated, dissolved in reducing sample buffer,
and separated on SDS-PAGE. Gel pieces with protein bands were cut
out, trypsinated, and analyzed using a matrix-associated laser
desorption ionization–time of flight instrument (MALDI micro MX,
Waters, Milford, MA). The masses of the fragments resulting from
trypsin digestion are determined using mass spectrometry. Experi-
mentally found patterns of fragment sizes are then compared with
information in databases, and proteins can thereby be identified.
Protein digestion and mass spectrometry were performed at the
Swegene proteomics resource center in Lund, Sweden (http://
www.lth.se/sciblu/services/proteomics). For further details, see
Supplementary Materials and Methods.
Amino-acid sequence analysis of proteins separated by
SDS-PAGE and transferred to polyvinylidene difluoride filters was
performed as previously described (Matsudaira, 1987; Brattsand and
Egelrud, 1999).
Cloning, purification, and characterization of recombinant
SPINK9 and epSPINK9
cDNA was produced from total RNA prepared from HaCaT
keratinocyte cell line as described (Brattsand and Egelrud, 1999)
using SuperScript III reversed transcriptase as recommended by the
vendor (Invitrogen, Carlsbad, CA). The cDNA was amplified in two
steps as described in Supplementary Materials and Methods and
inserted into the pET-32 EK/LIC vector according to the manual
(Novagen, Madison, WI). For protein production, the resulting
plasmids were expressed in E. coli OriB(DE3)pLysS as recommended
(Novagen). Recombinant protein was purified on a HisTrap HP
column (GE Healthcare, Freiburg, Germany). Tag sequences were
cleaved off using recombinant enterokinase (Novagen), and the
recombinant SPINK9/epSPINK9 was then purified by RPC, following
the same protocol as above. The purity of the recombinant protein
was analyzed by mass spectrometry performed at the IMBIM
proteomic resource center (Uppsala, Sweden; http://www.imbim.
uu.se/resource/proteomics.html; see Figure 1e).
Inhibitor concentration was determined by absorbance measure-
ments at 280 nm using a NanoDrop spectrophotometer (Thermo
Scientific, Waltham, MA). The extinction coefficient (E1%), based on
amino-acid composition, was set to 6.00 for SPINK9 and 6.60 for
epSPINK9, and the molecular weight used for calculations was 7731
and 7064 Da, respectively.
Surface plasmon resonance
Surface plasmon resonance is a technique and optical phenomenon
that is used to detect and quantify interactions between biomole-
cules monitored in real time. To perform an analysis, one interactant
(SPINK9 in this case) is immobilized on the matrix of a sensor ship.
Sample containing the other interactant (in our experiments, the
enzymes) is injected over the surface in a precisely controlled flow.
Binding events causes changes in the SPR signal and is monitored as
a sensorgram that expresses the resonance units as the function of
time. Protein–protein interaction experiments were performed on a
Biacore 2000 (Biacore, Uppsala, Sweden) using CM5 sensor chips
and HBS-EP buffer (10 mM HEPES, 0.15 M NaCl, 3 mM EDTA, 0.05%
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v/v Surfactant P20), pH 7.4. Eleven different concentrations were
used for the increase of affinity and kinetic parameters. For further
details, see Supplementary Materials and Methods.
Inhibition experiments
In inhibition experiments, enzyme, inhibitor, and buffer was mixed
and allowed to reach equilibrium for 15 minutes. Then chromogenic
substrate was added and initial cleavage rates were measured. For
further details, see figure legends and Supplementary Materials and
Methods.
To study the inhibition using macromolecular substrates, casein
and fibrinogen were tested. The EnzChek Protease Assay Kit (E6638,
Molecular Probes, Eugene, OR) was used essentially according to the
manufacturer’s instructions. Fibrinogen (Haemochrom Diagnostica,
Mo¨lndal, Sweden) was incubated with enzyme±SPINK9 inhibitor at
37 1C for different time periods. The resulting fibrinogen fragments
were then separated on 12% SDS-PAGE and visualized using
PageBlue (Fermentas). For further details, see figure legends and
Supplementary Materials and Methods.
Tissue preparation
Four-millimeter punch biopsies were taken from the skin of the
upper gluteal region or from palms of healthy human volunteers (two
males and two females aged 26–59 years) after written informed
consent and with the approval of the Human Research Ethics
Committee (Umea˚ University, reg. no. 00-004) and according to the
Declaration of Helsinki principles. Skin biopsies were either fixed in
buffered formaldehyde and embedded in paraffin according to
routine protocols or used for the preparation of total RNA using
TRIzol according to the manual (Invitrogen).
Immunohistochemistry
Serine protease inhibitor Kazal type 9-specific rabbit polyclonal
antibodies were raised by immunizing with a mixture of the
synthetic peptides and then reimmunizing the same rabbit with
nontagged, native recombinant SPINK9. Antibodies (Ce-SPINK9)
were affinity-purified on a column with recombinant SPINK9 still
containing the tag sequences. Adsorption experiments using
recombinant protein abolished the signal observed (data not shown).
Preparation and characterization of KLK5-specific antiserum Pe-C1
has been described elsewhere (Ekholm et al., 2000). LEKTI
antibodies were purchased from Zymed laboratories (San Francisco,
CA) (mouse anti-LEKTI clone 1C11G6). Secondary antibodies were
biotinylated horse anti-mouse or goat anti-rabbit (Vector Labora-
tories, Burlingame, CA). Immunohistochemistry was performed as
described before (Stefansson et al., 2006) using primary antibody
concentration 1mg ml1. For visualization, the avidin–biotin com-
plex ABC method (Vector Laboratories) was used with the
chromogenic substrate 3-amino-9-etylcarbazol (Dako Cytomation,
Solna, Sweden).
Expression of SPINK9 cDNA in human tissues
Total RNA was extracted as described above, and cDNA was
synthesized after DNase treatment using DNase I and SuperScript II
(Invitrogen) as recommended. PCR was performed on cDNA
prepared from skin biopsies as well as MTC panels I and II
purchased from CLONTECH (Mountain View, CA) using the
Advantage 2 Polymerase Mix as recommended. The number of
PCR cycles run is specified in Figures 6a and b. For further details,
see Supplementary Materials and Methods.
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